Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1994 Feb;69(2):253–259. doi: 10.1038/bjc.1994.48

TP53 allele loss, mutations and expression in malignant melanoma.

V A Flørenes 1, T Oyjord 1, R Holm 1, M Skrede 1, A L Børresen 1, J M Nesland 1, O Fodstad 1
PMCID: PMC1968671  PMID: 7905277

Abstract

p53 alterations at the DNA, mRNA and protein levels were studied in tumour metastases sampled from 30 patients with malignant melanoma. Paraffin-embedded sections from these and an additional 12 patients were examined for the presence of p53 protein. TP53 gene aberrations were found in 7 of 30 (23%) of the patients, six of which showed loss of heterozygosity (LOH). Point mutations were detected in only two cases, one of which had LOH whereas the other was non-informative. Increased levels of p53 mRNA were present in only one tumour with, but in six cases without, detectable DNA abnormalities. Four of the latter and six tumours with normal transcript levels had immunohistochemically detectable levels of p53 protein. In 25 cases in which corresponding primary and metastatic lesions could be compared, closely similar immunoreactivity patterns were observed. Increased expression of the MDM2 gene was found in only one tumour in parallel with overexpression of p53. Altogether, the data indicate that inactivation of the p53 regulatory pathway is not of major significance in the tumorigenesis of malignant melanoma. However, a significant association was found between p53 immunoreactivity and the relapse-free period in patients with superficial spreading melanoma. That increased protein expression was predominantly found in tumours without DNA alterations might suggest a role for the wild-type p53 protein in restricting malignant cell proliferation in these cases.

Full text

PDF
255

Images in this article

256Figure 2
on p.256

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Akslen L. A., Mørkve O. Expression of p53 protein in cutaneous melanoma. Int J Cancer. 1992 Aug 19;52(1):13–16. doi: 10.1002/ijc.2910520104. [DOI] [PubMed] [Google Scholar]
  2. Akslen L. A. P53 immunostaining in melanocytic lesions. Eur J Cancer. 1993;29A(4):652–653. doi: 10.1016/s0959-8049(05)80193-5. [DOI] [PubMed] [Google Scholar]
  3. Andreassen A., Oyjord T., Hovig E., Holm R., Flørenes V. A., Nesland J. M., Myklebost O., Høie J., Bruland O. S., Børresen A. L. p53 abnormalities in different subtypes of human sarcomas. Cancer Res. 1993 Feb 1;53(3):468–471. [PubMed] [Google Scholar]
  4. Ara S., Lee P. S., Hansen M. F., Saya H. Codon 72 polymorphism of the TP53 gene. Nucleic Acids Res. 1990 Aug 25;18(16):4961–4961. doi: 10.1093/nar/18.16.4961. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Barak Y., Juven T., Haffner R., Oren M. mdm2 expression is induced by wild type p53 activity. EMBO J. 1993 Feb;12(2):461–468. doi: 10.1002/j.1460-2075.1993.tb05678.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Bartek J., Iggo R., Gannon J., Lane D. P. Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines. Oncogene. 1990 Jun;5(6):893–899. [PubMed] [Google Scholar]
  7. Børresen A. L., Hovig E., Smith-Sørensen B., Malkin D., Lystad S., Andersen T. I., Nesland J. M., Isselbacher K. J., Friend S. H. Constant denaturant gel electrophoresis as a rapid screening technique for p53 mutations. Proc Natl Acad Sci U S A. 1991 Oct 1;88(19):8405–8409. doi: 10.1073/pnas.88.19.8405. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Caamano J., Ruggeri B. A., Klein-Szanto A. J. A catalog of p53 alterations in selected human and laboratory animal neoplasms. Prog Clin Biol Res. 1992;376:331–355. [PubMed] [Google Scholar]
  9. Chomczynski P., Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987 Apr;162(1):156–159. doi: 10.1006/abio.1987.9999. [DOI] [PubMed] [Google Scholar]
  10. Church G. M., Gilbert W. Genomic sequencing. Proc Natl Acad Sci U S A. 1984 Apr;81(7):1991–1995. doi: 10.1073/pnas.81.7.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Coles C., Condie A., Chetty U., Steel C. M., Evans H. J., Prosser J. p53 mutations in breast cancer. Cancer Res. 1992 Oct 1;52(19):5291–5298. [PubMed] [Google Scholar]
  12. Condie A., Eeles R., Borresen A. L., Coles C., Cooper C., Prosser J. Detection of point mutations in the p53 gene: comparison of single-strand conformation polymorphism, constant denaturant gel electrophoresis, and hydroxylamine and osmium tetroxide techniques. Hum Mutat. 1993;2(1):58–66. doi: 10.1002/humu.1380020111. [DOI] [PubMed] [Google Scholar]
  13. Davidoff A. M., Kerns B. J., Iglehart J. D., Marks J. R. Maintenance of p53 alterations throughout breast cancer progression. Cancer Res. 1991 May 15;51(10):2605–2610. [PubMed] [Google Scholar]
  14. Dolcetti R., Doglioni C., Maestro R., Gasparotto D., Barzan L., Pastore A., Romanelli M., Boiocchi M. p53 over-expression is an early event in the development of human squamous-cell carcinoma of the larynx: genetic and prognostic implications. Int J Cancer. 1992 Sep 9;52(2):178–182. doi: 10.1002/ijc.2910520204. [DOI] [PubMed] [Google Scholar]
  15. Feinberg A. P., Vogelstein B. A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity. Anal Biochem. 1983 Jul 1;132(1):6–13. doi: 10.1016/0003-2697(83)90418-9. [DOI] [PubMed] [Google Scholar]
  16. Fields S., Jang S. K. Presence of a potent transcription activating sequence in the p53 protein. Science. 1990 Aug 31;249(4972):1046–1049. doi: 10.1126/science.2144363. [DOI] [PubMed] [Google Scholar]
  17. Fountain J. W., Bale S. J., Housman D. E., Dracopoli N. C. Genetics of melanoma. Cancer Surv. 1990;9(4):645–671. [PubMed] [Google Scholar]
  18. Hall P. A., McKee P. H., Menage H. D., Dover R., Lane D. P. High levels of p53 protein in UV-irradiated normal human skin. Oncogene. 1993 Jan;8(1):203–207. [PubMed] [Google Scholar]
  19. Hollstein M., Sidransky D., Vogelstein B., Harris C. C. p53 mutations in human cancers. Science. 1991 Jul 5;253(5015):49–53. doi: 10.1126/science.1905840. [DOI] [PubMed] [Google Scholar]
  20. Holm R., Skomedal H., Helland A., Kristensen G., Børresen A. L., Nesland J. M. Immunohistochemical analysis of p53 protein overexpression in normal, premalignant, and malignant tissues of the cervix uteri. J Pathol. 1993 Jan;169(1):21–26. doi: 10.1002/path.1711690105. [DOI] [PubMed] [Google Scholar]
  21. Hovig E., Smith-Sørensen B., Brøgger A., Børresen A. L. Constant denaturant gel electrophoresis, a modification of denaturing gradient gel electrophoresis, in mutation detection. Mutat Res. 1991 Jan;262(1):63–71. doi: 10.1016/0165-7992(91)90108-g. [DOI] [PubMed] [Google Scholar]
  22. Hsu S. M., Raine L., Fanger H. A comparative study of the peroxidase-antiperoxidase method and an avidin-biotin complex method for studying polypeptide hormones with radioimmunoassay antibodies. Am J Clin Pathol. 1981 May;75(5):734–738. doi: 10.1093/ajcp/75.5.734. [DOI] [PubMed] [Google Scholar]
  23. Hultman T., Ståhl S., Hornes E., Uhlén M. Direct solid phase sequencing of genomic and plasmid DNA using magnetic beads as solid support. Nucleic Acids Res. 1989 Jul 11;17(13):4937–4946. doi: 10.1093/nar/17.13.4937. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Høyheim B., Nakamura Y., White R. A BamHI-polymorphism is detected by a genomic p53-clone (pBHP53). Nucleic Acids Res. 1989 Nov 11;17(21):8898–8898. doi: 10.1093/nar/17.21.8898. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Iggo R., Gatter K., Bartek J., Lane D., Harris A. L. Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet. 1990 Mar 24;335(8691):675–679. doi: 10.1016/0140-6736(90)90801-b. [DOI] [PubMed] [Google Scholar]
  26. Isobe M., Emanuel B. S., Givol D., Oren M., Croce C. M. Localization of gene for human p53 tumour antigen to band 17p13. Nature. 1986 Mar 6;320(6057):84–85. doi: 10.1038/320084a0. [DOI] [PubMed] [Google Scholar]
  27. Kastan M. B., Onyekwere O., Sidransky D., Vogelstein B., Craig R. W. Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 1991 Dec 1;51(23 Pt 1):6304–6311. [PubMed] [Google Scholar]
  28. Koh H. K. Cutaneous melanoma. N Engl J Med. 1991 Jul 18;325(3):171–182. doi: 10.1056/NEJM199107183250306. [DOI] [PubMed] [Google Scholar]
  29. Kondoleon S., Vissing H., Luo X. Y., Magenis R. E., Kellogg J., Litt M. A hypervariable RFLP on chromosome 17p13 is defined by an arbitrary single copy probe p144-D6 [HGM9 No. D17S34]. Nucleic Acids Res. 1987 Dec 23;15(24):10605–10605. doi: 10.1093/nar/15.24.10605. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Kraiss S., Quaiser A., Oren M., Montenarh M. Oligomerization of oncoprotein p53. J Virol. 1988 Dec;62(12):4737–4744. doi: 10.1128/jvi.62.12.4737-4744.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Ladanyi M., Cha C., Lewis R., Jhanwar S. C., Huvos A. G., Healey J. H. MDM2 gene amplification in metastatic osteosarcoma. Cancer Res. 1993 Jan 1;53(1):16–18. [PubMed] [Google Scholar]
  32. Lassam N. J., From L., Kahn H. J. Overexpression of p53 is a late event in the development of malignant melanoma. Cancer Res. 1993 May 15;53(10 Suppl):2235–2238. [PubMed] [Google Scholar]
  33. Lehman T. A., Bennett W. P., Metcalf R. A., Welsh J. A., Ecker J., Modali R. V., Ullrich S., Romano J. W., Appella E., Testa J. R. p53 mutations, ras mutations, and p53-heat shock 70 protein complexes in human lung carcinoma cell lines. Cancer Res. 1991 Aug 1;51(15):4090–4096. [PubMed] [Google Scholar]
  34. Levine A. J., Momand J., Finlay C. A. The p53 tumour suppressor gene. Nature. 1991 Jun 6;351(6326):453–456. doi: 10.1038/351453a0. [DOI] [PubMed] [Google Scholar]
  35. McDaniel T., Carbone D., Takahashi T., Chumakov P., Chang E. H., Pirollo K. F., Yin J., Huang Y., Meltzer S. J. The MspI polymorphism in intron 6 of p53 (TP53) detected by digestion of PCR products. Nucleic Acids Res. 1991 Sep 11;19(17):4796–4796. doi: 10.1093/nar/19.17.4796-a. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Momand J., Zambetti G. P., Olson D. C., George D., Levine A. J. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell. 1992 Jun 26;69(7):1237–1245. doi: 10.1016/0092-8674(92)90644-r. [DOI] [PubMed] [Google Scholar]
  37. Nakamura Y., Ballard L., Leppert M., O'Connell P., Lathrop G. M., Lalouel J. M., White R. Isolation and mapping of a polymorphic DNA sequence (pYNZ22) on chromosome 17p [D17S30]. Nucleic Acids Res. 1988 Jun 24;16(12):5707–5707. doi: 10.1093/nar/16.12.5707. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Naylor S. L., Sakaguchi A. Y., Barker D., White R., Shows T. B. DNA polymorphic loci mapped to human chromosomes 3, 5, 9, 11, 17, 18, and 22. Proc Natl Acad Sci U S A. 1984 Apr;81(8):2447–2451. doi: 10.1073/pnas.81.8.2447. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Nigro J. M., Baker S. J., Preisinger A. C., Jessup J. M., Hostetter R., Cleary K., Bigner S. H., Davidson N., Baylin S., Devilee P. Mutations in the p53 gene occur in diverse human tumour types. Nature. 1989 Dec 7;342(6250):705–708. doi: 10.1038/342705a0. [DOI] [PubMed] [Google Scholar]
  40. Oliner J. D., Kinzler K. W., Meltzer P. S., George D. L., Vogelstein B. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature. 1992 Jul 2;358(6381):80–83. doi: 10.1038/358080a0. [DOI] [PubMed] [Google Scholar]
  41. Osborne R. J., Merlo G. R., Mitsudomi T., Venesio T., Liscia D. S., Cappa A. P., Chiba I., Takahashi T., Nau M. M., Callahan R. Mutations in the p53 gene in primary human breast cancers. Cancer Res. 1991 Nov 15;51(22):6194–6198. [PubMed] [Google Scholar]
  42. Pignatelli M., Stamp G. W., Kafiri G., Lane D., Bodmer W. F. Over-expression of p53 nuclear oncoprotein in colorectal adenomas. Int J Cancer. 1992 Mar 12;50(5):683–688. doi: 10.1002/ijc.2910500503. [DOI] [PubMed] [Google Scholar]
  43. Reifenberger G., Liu L., Ichimura K., Schmidt E. E., Collins V. P. Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations. Cancer Res. 1993 Jun 15;53(12):2736–2739. [PubMed] [Google Scholar]
  44. Rivas C. I., Wisniewski D., Strife A., Perez A., Lambek C., Bruno S., Darzynkiewicz Z., Clarkson B. Constitutive expression of p53 protein in enriched normal human marrow blast cell populations. Blood. 1992 Apr 15;79(8):1982–1986. [PubMed] [Google Scholar]
  45. Sauter E. R., Ridge J. A., Gordon J., Eisenberg B. L. p53 overexpression correlates with increased survival in patients with squamous carcinoma of the tongue base. Am J Surg. 1992 Dec;164(6):651–653. doi: 10.1016/s0002-9610(05)80727-5. [DOI] [PubMed] [Google Scholar]
  46. Sidransky D., Mikkelsen T., Schwechheimer K., Rosenblum M. L., Cavanee W., Vogelstein B. Clonal expansion of p53 mutant cells is associated with brain tumour progression. Nature. 1992 Feb 27;355(6363):846–847. doi: 10.1038/355846a0. [DOI] [PubMed] [Google Scholar]
  47. Stretch J. R., Gatter K. C., Ralfkiaer E., Lane D. P., Harris A. L. Expression of mutant p53 in melanoma. Cancer Res. 1991 Nov 1;51(21):5976–5979. [PubMed] [Google Scholar]
  48. Thor A. D., Moore DH I. I., Edgerton S. M., Kawasaki E. S., Reihsaus E., Lynch H. T., Marcus J. N., Schwartz L., Chen L. C., Mayall B. H. Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. J Natl Cancer Inst. 1992 Jun 3;84(11):845–855. doi: 10.1093/jnci/84.11.845. [DOI] [PubMed] [Google Scholar]
  49. Tobal K., Warren W., Cooper C. S., McCartney A., Hungerford J., Lightman S. Increased expression and mutation of p53 in choroidal melanoma. Br J Cancer. 1992 Nov;66(5):900–904. doi: 10.1038/bjc.1992.382. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Toguchida J., Yamaguchi T., Ritchie B., Beauchamp R. L., Dayton S. H., Herrera G. E., Yamamuro T., Kotoura Y., Sasaki M. S., Little J. B. Mutation spectrum of the p53 gene in bone and soft tissue sarcomas. Cancer Res. 1992 Nov 15;52(22):6194–6199. [PubMed] [Google Scholar]
  51. Vogelstein B. Cancer. A deadly inheritance. Nature. 1990 Dec 20;348(6303):681–682. doi: 10.1038/348681a0. [DOI] [PubMed] [Google Scholar]
  52. Volkenandt M., Schlegel U., Nanus D. M., Albino A. P. Mutational analysis of the human p53 gene in malignant melanoma. Pigment Cell Res. 1991 Feb;4(1):35–40. doi: 10.1111/j.1600-0749.1991.tb00311.x. [DOI] [PubMed] [Google Scholar]
  53. Wynford-Thomas D. P53 in tumour pathology: can we trust immunocytochemistry? J Pathol. 1992 Apr;166(4):329–330. doi: 10.1002/path.1711660402. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES